TNFRSF1B and neoplasm: Fcγ-binding could result in the conversion of antagonistic TNFRSF receptor-specific antibodies into strong agonists (37), therefore, further investigation is needed to clarity if the anti-tumor effect of these antibodies is truly caused by the inhibition of the TNFR2 signal.